Cancer Advisor | One Day MD

Medically reviewed by: Dr. Frank Yap, MD  |  Written by: OneDayMD Editorial Team  |  Last updated: October 17, 2026 (v3.0) Quick Answer (AI & search summary). The OneDayMD colorectal compilation now lists 87 items, but they represent about 64 unique patients plus one 40-patient randomized trial (two patients were counted 2–3 times). About 82% are standard colon or rectal adenocarcinoma; 12 entries are rarer subtypes (4 neuroendocrine, 3 appendiceal, 2 squamous, 1 signet-ring, 1 mucinous, 1 colon+gastric dual primary), and 7 of those are not colorectal at all. About 20 unique patients (31%) report a biomarker , almost all CEA or CA 19-9 falling during chemotherapy; only 1 reports tumor genotype, 2 report ctDNA, and none report MMR/MSI status . Only 3 entries explicitly describe no conventional therapy, and 2 of those are indolent neuroendocrine tumors. The only controlled evidence is the Hegazy 2022 mebendazole trial (n=40). Evidence tier: CEBM Lev...

Medically reviewed by Dr. Frank Yap, MD | Written by OneDayMD Editorial Team | First published October 1, 2026 | Updated October 17, 2026 (v3.0) Source disclosure. 48 of the 63 entries (76%) come from posts by one individual, William Makis, with an ivermectin cancer clinic in Florida. Five entries (50–54) come from Leading Edge Clinic (Dr. Pierre Kory). The rest are anonymous patient or family testimonials. None was independently verified. Quick Answer The primary case series lists 63 entries. After removing 7 non-analyzable entries and 4 duplicate patients, 52 unique lung-primary patients remain. Small cell lung cancer (SCLC): 8 patients (15.4%), Cases 1, 4, 23, 28, 30, 41, 46, 57. Biomarker-defined: 13 patients (25.0%). Four state a driver (EGFR ×3, ALK ×1); nine more imply one through a named targeted drug. None reports PD-L1, TMB or a sequencing panel. Immunotherapy: 9 patients (17.3%), plus 1 head-and-neck primary with lung metastases. Concurrent standard the...

Comparative evidence review • Experimental oncology • Biomarker hypothesis generation Abstract Background: Antiparasitic drugs have attracted interest as potential repurposed anticancer compounds because several demonstrate cytotoxic, anti-proliferative, metabolic, anti-angiogenic or signaling effects in experimental cancer models. Fenbendazole and mebendazole are benzimidazole anthelmintics with overlapping microtubule-related pharmacology, whereas ivermectin is a macrocyclic lactone with a substantially different molecular profile. A simple “antiparasitic drugs kill cancer cells” framework, however, obscures potentially important genotype and phenotype dependencies. Objective: To construct a comparative cancer biomarker map for fenbendazole (FBZ), mebendazole (MBZ), and ivermectin (IVM), focusing on TP53, MDM2, MDM4/MDMX, KRAS, EGFR, MYC, BRAF, RB1, CDKN2A, GLUT1, HK2, PAK1, YAP1, Wnt/β-catenin, PI3K/Akt/mTOR and related cellular phenotypes. Methods: Experimental, tr...